QC
ALNY icon

Quadrature Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quadrature Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.82M Sell
22,653
-62,588
-73% -$18.9M 0.06% 236
2026
Q1 		$28.2M Buy
+85,241
New +$29M 0.34% 69
2025
Q4 		– Sell
-48,920
Closed -$22.3M – 1235
2025
Q3 		$22.3M Buy
48,920
+47,033
+2,492% +$19.2M 0.26% 85
2025
Q2 		$615K Sell
1,887
-16,624
-90% -$4.6M 0.01% 515
2025
Q1 		$5M Buy
+18,511
New +$4.76M 0.11% 174

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrature Capital's ALNY Position: Q2 2026 in Review

Quadrature Capital reduced its Alnylam Pharmaceuticals (ALNY) stake by 73% in Q2 2026, selling an estimated $18.9M and leaving 22,653 shares worth $6.82M. The position accounts for 0.06% of the portfolio, ranked #236.

Quadrature Capital first reported a position in ALNY in Q1 2025 and has held it in 5 quarters since. The position peaked at $28.2M in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Quadrature Capital held 22,653 shares of Alnylam Pharmaceuticals worth $6.82M as of Q2 2026.
  • Quadrature Capital sold 62,588 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $18.9M.
  • Alnylam Pharmaceuticals made up 0.06% of Quadrature Capital's portfolio in Q2 2026, its #236 holding.
  • Quadrature Capital first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Alnylam Pharmaceuticals position peaked at $28.2M in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.